Editas Medicine, an early gene-editing biotech company, laid off 20% of its workforce in January 2023 as part of a strategic restructuring to streamline its pipeline and operations. The layoffs coincided with the departure of its Chief Scientific Officer and were announced ahead of the J.P. Morgan Healthcare Conference. The company, which has faced challenges in advancing its clinical programs, made these cuts to prioritize key research and development efforts and extend its financial runway in a difficult market for the biotechnology industry.
